Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Procrit Documents Subpoenaed By HHS Inspector General

This article was originally published in The Pink Sheet Daily

Executive Summary

The subpoena requests documents related to sales and marketing of the anemia treatment, Johnson & Johnson says. Procrit is also under scrutiny by the New York Attorney General.

You may also be interested in...



J&J Is Spitzer's Next Target: New York AG Opens Broad Off-Label Promotion Investigation

Procrit, Risperdal and four other leading J&J pharmaceutical brands are the subject of a document request from New York Attorney General Eliot Spitzer. J&J is already facing two federal investigations into marketing practices.

Effexor Latest Target Of U.S. Office Of Personnel Management Investigation Into Rx Marketing

OPM appears to be conducting a wide-ranging investigation into mental health drug marketing. Forest, J&J and Wyeth have received subpoenas from the agency that oversees Federal Employees Health Benefits Program.

Lupus Guidance Suggests Broad Use Of Health-Related Quality Of Life Endpoint

FDA’s draft guidance on systemic lupus erythematosus drug development lists four possible claims that the agency “may be willing to approve”: reduction in disease activity; organ-specific lupus treatment; complete clinical response/remission; and reduction in flares.

Topics

UsernamePublicRestriction

Register

LL1135495

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel